Clene Inc.
NASDAQ:CLNNBiotechnology
+$0.08 today
- Market cap
- $52.70M
- Beta
- 0.92
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$2.88
Volume 0.12M
Average 0.50M
CLNN Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Clene Inc.NASDAQ: CLNN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $355K fell 12.1% year over year, behind the -11.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.4% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.
Context
- Depreciation & amortization amounted to 747.5% of revenue in FY2025, up 266.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -12.1% toward the trailing-twelve-month pace of -11.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.5M USD
- Year-over-year change
- -9.1%
- 4-year CAGR
- +11.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.5M | -9.1% |
| FY2024 | 2024-12-31 | 1.65M | -3.5% |
| FY2023 | 2023-12-31 | 1.71M | +67.3% |
| FY2022 | 2022-12-31 | 1.02M | +6.7% |
| FY2021 | 2021-12-31 | 955K | — |
Depreciation & Amortization vs competitors
How CLNN compares with its peers on the latest reported figures
- CLNN's LTM Mar 2026 depreciation & amortization of $1.45M is the 4th highest of the 11 companies compared; the peer median is $397.5K.
- Its year-over-year change of -11.2% is the 5th highest of 11, against a peer median of -20.7%.
- Depreciation & amortization amounts to 1079.1% of revenue for CLNN, versus a peer median of 4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.09M | -5.1% | -15.4% | 4.5% | |
| LTM Mar 2026 | $3.64M | -3.9% | +6.3% | 364.3% | |
| LTM Mar 2026 | $1.51M | -26.6% | -22.8% | — | |
| LTM Mar 2026 | $1.45M | -11.2% | +13.6% | 1079.1% | |
| FY2025 | $704K | +6.7% | -11.9% | 1100.0% | |
| LTM Mar 2026 | $628K | -48.8% | -19.7% | — | |
| LTM Mar 2026 | $167K | -73.0% | -39.9% | 2.3% | |
| LTM Mar 2026 | $121K | -27.5% | -67.8% | — | |
| LTM Mar 2026 | $48.3K | +290.5% | +20.6% | — | |
| LTM Mar 2026 | $23.33K | -14.7% | +0.0% | 0.3% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $22K | -88.5% | -20.8% | — |
| Peer median (excluding CLNN) | $397.5K | -20.7% | -17.6% | 4.5% | |
Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 723K | 473K | 654K | 342K | 200K |
| Cost of Revenue | 289K | 26K | 121K | 70K | 43K |
| Gross Profit | 434K | 447K | 533K | 272K | 157K |
| Gross Margin | 60.0% | 94.5% | 81.5% | 79.5% | 78.5% |
| Research & Development | 28.42M | 31.92M | 26.66M | 20.06M | 14.01M |
| Selling, General & Admin | 18.81M | 16.16M | 14.42M | 13.31M | 9.23M |
| Operating Expenses | 50.41M | 48.86M | 41.07M | 33.37M | 23.24M |
| Depreciation & Amortization | 955K | 1.02M | 1.71M | 1.65M | 1.5M |
| EBITDA | (8.34M) | (25.6M) | (43.24M) | (33.69M) | (22M) |
| EBITDA Margin | -1153.9% | -5412.9% | -6611.8% | -9851.2% | -10998.0% |
| Operating Income | (49.98M) | (48.41M) | (40.54M) | (33.09M) | (23.08M) |
| Operating Margin | -6912.6% | -10234.5% | -6198.8% | -9676.3% | -11541.5% |
| Interest Income | 0 | 0 | 1.39M | 865K | 223K |
| Interest Expense | 870K | 3.3M | 4.56M | 4.06M | 2.68M |
| Other Income / Expenses | 39.81M | 18.49M | (8.96M) | (6.31M) | (3.09M) |
| Income Before Tax | (10.17M) | (29.92M) | (49.5M) | (39.4M) | (26.17M) |
| Pre-Tax Margin | -1406.4% | -6325.2% | -7569.4% | -11520.5% | -13086.5% |
| Income Tax Expense | (428K) | 0 | 0 | 0 | 0 |
| Net Income | (9.74M) | (29.92M) | (49.5M) | (39.4M) | (26.17M) |
| Net Margin | -1347.2% | -6325.2% | -7569.4% | -11520.5% | -13086.5% |
| EPS (Basic) | (3.16) | (4.69) | (9.43) | (5.67) | (2.65) |
| EPS (Diluted) | (3.16) | (4.69) | (9.43) | (5.67) | (2.65) |
| Weighted Avg Shares | 3.08M | 3.26M | 5.25M | 6.95M | 9.86M |
| Weighted Avg Shares (Diluted) | 3.08M | 3.26M | 5.25M | 6.95M | 9.86M |
Clene Inc.
NASDAQ:CLNN
Intrinsic Alpha fair value
Locked
Current Price
$3.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.